Batbaatar, Batchimeg

Now showing 1 - 2 of 2

Some of the metrics are blocked by your
consent settings
The Impact of GPC3 rs2267531 Polymorphism on Hepatocellular Carcinoma Susceptibility
(Mongolian National University of Medical Sciences, 2025-03-31)
Batchimeg Batbaatar
;
Yesukhei Enkhbat
;
Odonchimeg Tuvshiunsaikhan
;
Yundendash Dashzeveg
;
Munkhtsetseg Bat-Erdene
Objectives: To evaluate the association between the GPC3 rs2267531 polymorphism and hepatocellular carcinoma (HCC) in individuals from Mongolia. Methods: This study included 270 participants, consisting of 110 males and 160 females, with a mean age of 61.0 years (±9.5). Serum samples were collected from all participants, who were categorized into three groups: 90 patients with hepatocellular carcinoma (HCC), 90 individuals in the risk group (RG), and 90 healthy controls. The collected samples were analyzed using allele-specific polymerase chain reaction (PCR). Results: No significant differences in genotype and allele frequencies were observed between the HCC group and the risk or control groups. However, the frequency of the GPC3 C allele was significantly higher in females in the HCC group. Additionally, the protective GG genotype of GPC3 was found to have a significantly lower frequency in females in the HCC group. In contrast, HCV-positive individuals exhibited a higher frequency of the GC genotype. Conclusion: The GPC3 C allele frequency is associated with HCC in females, while the heterozygote GC genotype is linked to HCV infection in both genders. These findings suggest that the GPC3 rs2267531 polymorphism may play a role in HCC susceptibility, particularly in relation to gender and HCV status.
Some of the metrics are blocked by your
consent settings
Evaluation of glypican‑3 in patients with hepatocellular carcinoma
(2025-01)
Batbaatar, Batchimeg
;
Gurbadam, Unenbat
;
Tuvshinsaikhan, Odonchimeg
;
Narmandakh, Nyam-Erdene
;
Khatanbaatar, Gerelee
Hepatocellular carcinoma (HCC) is one of the most common cancers occurring worldwide, including Mongolia. Although alpha-fetoprotein (AFP) is a widely used marker for HCC, conflicting studies have been published regarding its specificity and sensitivity towards HCC. Glypican-3 (GPC3) is a different promising biomarker for HCC, and there is some evidence to suggest that this protein may be a more specific marker compared with AFP. GPC3 has been shown to fulfill important roles in cell proliferation and division during embryogenesis, and is rarely found in the tissues of healthy adults. The aim of the present study was to investigate the levels of serum GPC3 (sGPC3) and tissue GPC3 in Mongolian patients with HCC. Serum samples from a total of 270 individuals [HCC group, 90 patients; risk group (RG), 90 subjects; and control group, 90 subjects] were evaluated using enzyme-linked immunosorbent assay to identify the sGPC3 levels. In addition, immunohistochemical analysis of the GPC3 was performed on tissue samples from 50 patients with HCC to evaluate the expression of GPC3. sGPC3 level was found to be significantly increased in the HCC group compared with the RG and the control group, with the area under the curve=0.85 (P<0.001). sGPC3 was found to be significantly associated with hepatitis C virus status and cirrhosis (P<0.05). In addition, the tissue expression of GPC3 was associated with the serum AFP (sAFP) level. Finally, positive staining of GPC3 was observed when the sAFP level of the patient was >20 ng/ml. In conclusion, the results from the present study have supported that GPC3 may be a promising marker for HCC, and can be used as a diagnostic marker alongside AFP.
Scopus© Citations 8

Batbaatar, Batchimeg

Filters

Settings

Sort By

Results per page